Stock listing
ASX:SPL Starpharma Holdings Limited Share Price
Home listing (ASX) of Starpharma Holdings Limited
Follow Starpharma Holdings Limited into a list and get an email when it puts out news.
Share price · ASX:SPL
$0.42 AUD -0.01 (-1.2%)
Close on Nov 20, 2026
- Day range
- $0.405 – $0.42 AUDNov 20, 2026
- Volume
- 772,892 sharesNov 20, 2026
- Market cap
- $201.5M AUDAt the close on Nov 20, 2026 · price × 479.7M shares outstanding
- 52-week range
- $0.32 – $0.875 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.39M AUDMedian day 1.60M shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:SPL · Home | $0.42 AUD | -0.005 (-1.2%) | 772,892 | $0.41 | $0.42 | $0.405 | $0.425 | Close on Nov 20, 2026 |
| OTC:SPHRF | $0.32 USD | 0.00 (0.0%) | — | $0.32 | $0.32 | $0.32 | $0.32 | Close on Nov 6, 2026 |
| OTC:SPHRY | $3.21 USD | 0.00 (0.0%) | — | $3.21 | $3.21 | $3.21 | $3.21 | Close on Nov 6, 2026 |
| Frankfurt:PQ6 | €0.242 EUR | +0.002 (+0.8%) | — | €0.242 | €0.242 | €0.242 | €0.240 | Close on Nov 20, 2026 |
| Munich:PQ6 | €0.262 EUR | -0.004 (-1.5%) | — | €0.262 | €0.262 | €0.262 | €0.266 | Close on Nov 20, 2026 |
| Stuttgart:PQ6 | €0.24 EUR | +0.002 (+0.8%) | — | €0.246 | €0.246 | €0.24 | €0.238 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:SPL · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.42 | -0.005 | -1.2% | $0.41 | $0.42 | $0.405 | 772,892 | |
| $0.425 | +0.01 | +2.4% | $0.415 | $0.43 | $0.415 | 171,027 | |
| $0.415 | -0.005 | -1.2% | $0.42 | $0.42 | $0.41 | 745,355 | |
| $0.42 | -0.005 | -1.2% | $0.425 | $0.435 | $0.42 | 363,167 | |
| $0.425 | 0.00 | 0.0% | $0.42 | $0.442 | $0.42 | 542,640 | |
| $0.425 | 0.00 | 0.0% | $0.427 | $0.435 | $0.42 | 753,365 | |
| $0.425 | +0.015 | +3.7% | $0.42 | $0.435 | $0.415 | 688,948 | |
| $0.41 | -0.04 | -8.9% | $0.45 | $0.45 | $0.405 | 1,307,637 | |
| $0.45 | +0.005 | +1.1% | $0.455 | $0.465 | $0.445 | 319,305 | |
| $0.445 | -0.015 | -3.3% | $0.46 | $0.46 | $0.44 | 508,466 | |
| $0.46 | +0.005 | +1.1% | $0.46 | $0.485 | $0.46 | 890,979 | |
| $0.455 | 0.00 | 0.0% | $0.47 | $0.477 | $0.455 | 931,127 | |
| $0.455 | +0.02 | +4.6% | $0.44 | $0.46 | $0.44 | 890,748 | |
| $0.435 | -0.015 | -3.3% | $0.45 | $0.455 | $0.43 | 923,051 | |
| $0.45 | +0.02 | +4.7% | $0.43 | $0.46 | $0.42 | 1,693,181 | |
| $0.43 | -0.03 | -6.5% | $0.46 | $0.475 | $0.43 | 1,186,114 | |
| $0.46 | +0.015 | +3.4% | $0.45 | $0.475 | $0.44 | 850,991 | |
| $0.445 | -0.03 | -6.3% | $0.475 | $0.483 | $0.445 | 1,587,068 | |
| $0.475 | +0.01 | +2.2% | $0.45 | $0.49 | $0.445 | 2,070,086 | |
| $0.465 | -0.005 | -1.1% | $0.455 | $0.465 | $0.435 | 1,528,036 | |
| $0.47 | -0.01 | -2.1% | $0.49 | $0.505 | $0.47 | 3,326,752 | |
| $0.48 | -0.02 | -4.0% | $0.52 | $0.535 | $0.47 | 6,005,409 | |
| $0.50 | -0.25 | -33.3% | $0.75 | $0.75 | $0.49 | 10,307,969 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | -0.05 | -6.3% | $0.80 | $0.805 | $0.73 | 2,420,375 | |
| $0.80 | -0.03 | -3.6% | $0.83 | $0.83 | $0.80 | 1,148,946 | |
| $0.83 | -0.02 | -2.4% | $0.845 | $0.848 | $0.825 | 2,209,167 | |
| $0.85 | +0.005 | +0.6% | $0.83 | $0.86 | $0.83 | 2,594,664 | |
| $0.845 | +0.01 | +1.2% | $0.835 | $0.85 | $0.83 | 2,438,535 | |
| $0.835 | +0.005 | +0.6% | $0.83 | $0.845 | $0.823 | 1,291,818 | |
| $0.83 | +0.015 | +1.8% | $0.81 | $0.845 | $0.81 | 1,870,722 | |
| $0.815 | +0.005 | +0.6% | $0.82 | $0.82 | $0.795 | 2,640,252 | |
| $0.81 | +0.01 | +1.3% | $0.805 | $0.82 | $0.805 | 1,877,109 | |
| $0.80 | +0.005 | +0.6% | $0.82 | $0.82 | $0.78 | 4,014,505 | |
| $0.795 | -0.075 | -8.6% | $0.87 | $0.87 | $0.78 | 4,785,289 | |
| $0.87 | +0.035 | +4.2% | $0.83 | $0.875 | $0.825 | 984,546 | |
| $0.835 | +0.015 | +1.8% | $0.825 | $0.835 | $0.81 | 1,209,387 | |
| $0.82 | -0.02 | -2.4% | $0.855 | $0.86 | $0.81 | 944,407 | |
| $0.84 | +0.025 | +3.1% | $0.815 | $0.84 | $0.795 | 3,062,860 | |
| $0.815 | 0.00 | 0.0% | $0.82 | $0.82 | $0.805 | 1,510,635 | |
| $0.815 | +0.005 | +0.6% | $0.805 | $0.85 | $0.80 | 3,219,304 | |
| $0.81 | +0.015 | +1.9% | $0.795 | $0.815 | $0.788 | 4,511,884 | |
| $0.795 | -0.005 | -0.6% | $0.79 | $0.805 | $0.77 | 2,893,139 | |
| $0.80 | +0.03 | +3.9% | $0.78 | $0.80 | $0.775 | 3,537,042 | |
| $0.77 | +0.01 | +1.3% | $0.75 | $0.775 | $0.75 | 3,527,198 | |
| $0.76 | +0.015 | +2.0% | $0.745 | $0.765 | $0.735 | 1,798,686 | |
| $0.745 | +0.005 | +0.7% | $0.74 | $0.75 | $0.74 | 1,697,837 | |
| $0.74 | +0.035 | +5.0% | $0.715 | $0.74 | $0.715 | 1,617,584 | |
| $0.705 | -0.08 | -10.2% | $0.78 | $0.78 | $0.705 | 3,969,078 | |
| $0.785 | -0.025 | -3.1% | $0.805 | $0.83 | $0.785 | 1,914,746 | |
| $0.81 | 0.00 | 0.0% | $0.80 | $0.83 | $0.785 | 2,866,972 | |
| $0.81 | +0.015 | +1.9% | $0.80 | $0.815 | $0.77 | 2,108,483 | |
| $0.795 | +0.04 | +5.3% | $0.755 | $0.82 | $0.755 | 3,723,427 | |
| $0.755 | +0.02 | +2.7% | $0.73 | $0.77 | $0.73 | 1,175,866 | |
| $0.735 | +0.015 | +2.1% | $0.72 | $0.74 | $0.72 | 1,055,477 | |
| $0.72 | 0.00 | 0.0% | $0.72 | $0.725 | $0.71 | 773,320 | |
| $0.72 | 0.00 | 0.0% | $0.73 | $0.73 | $0.715 | 895,344 | |
| $0.72 | +0.005 | +0.7% | $0.725 | $0.74 | $0.715 | 2,835,328 | |
| $0.715 | 0.00 | 0.0% | $0.725 | $0.725 | $0.715 | 175,657 | |
| $0.715 | -0.01 | -1.4% | $0.73 | $0.735 | $0.695 | 2,968,864 | |
| $0.725 | -0.005 | -0.7% | $0.73 | $0.745 | $0.725 | 869,024 | |
| $0.73 | +0.005 | +0.7% | $0.73 | $0.755 | $0.725 | 1,013,712 | |
| $0.725 | -0.005 | -0.7% | $0.73 | $0.745 | $0.72 | 2,549,841 | |
| $0.73 | -0.03 | -3.9% | $0.75 | $0.78 | $0.728 | 3,486,167 | |
| $0.76 | +0.035 | +4.8% | $0.725 | $0.77 | $0.725 | 3,853,631 |
- Ticker
- ASX:SPL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 6, 2026
Chair and Deputy Chair Appointments
Latest deck · Nov 6, 2026
Shareholder Meeting (November 2026)
Shareholder meeting · 31 slides
Latest news
Chair and Deputy Chair Appointments
Nov 5, 2026
Closed $0.445 (-3.3%) on Nov 6, 2026
Results of 2026 Annual General Meeting
Nov 5, 2026
Closed $0.445 (-3.3%) on Nov 6, 2026
AGM Chair address and CEO presentation
Nov 5, 2026
Closed $0.445 (-3.3%) on Nov 6, 2026
Becoming a substantial holder
Nov 2, 2026
Closed $0.455 (+4.6%) on Nov 3, 2026
Application for quotation of securities - SPL
Oct 29, 2026
Closed $0.45 (+4.7%) on Oct 30, 2026
Application for quotation of securities - SPL
Oct 29, 2026
Closed $0.45 (+4.7%) on Oct 30, 2026
Details of Company Address
Oct 23, 2026
Closed $0.475 (+2.2%) on Oct 26, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 21, 2026
Closed $0.47 (-2.1%) on Oct 22, 2026
$3.5 Million R&D Tax Incentive Received
Oct 21, 2026
Closed $0.47 (-2.1%) on Oct 22, 2026
Starpharma Investor Presentation Petalion Webinar
Oct 20, 2026
Closed $0.48 (-4.0%) on Oct 21, 2026
Starpharma Holdings Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 52 in the last 12 months · 308 in all · newest Nov 6, 2026 · oldest 2016
- Decks
- 67 decks · latest Nov 6, 2026
Where Starpharma Holdings Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:SPL · Home listing · This page | ASX | Australia | AUD |
| OTC:SPHRF | OTC | United States | USD |
| OTC:SPHRY | OTC | United States | USD |
| Lang & Schwarz:796461 | Lang & Schwarz | Germany | EUR |
| LS Exchange:796461 | LS Exchange | Germany | EUR |
| gettex:PQ6 | gettex | Germany | EUR |
| Dusseldorf:PQ6 | Dusseldorf | Germany | EUR |
| Frankfurt:PQ6 | Frankfurt | Germany | EUR |
| Hamburg:PQ6 | Hamburg | Germany | EUR |
| BX Swiss:PQ6 | BX Swiss | Switzerland | CHF |
| Frankfurt:PQ6A | Frankfurt | Germany | EUR |
| Munich:PQ6 | Munich | Germany | EUR |
| Stuttgart:PQ6 | Stuttgart | Germany | EUR |
Valuation
EV/sales 15.9× against a median of 17.5×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $191.2M AUD
- P/E
- Loss
- EV/sales
- 15.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 14.6×
- Gross margin
- 86.3%
- Operating margin
- −159.6%
- Net margin
- −62.0%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Starpharma Holdings Limited · ASX:SPL | US$133.7M | US$126.9M | n/a | 15.9× | n/a | 14.6× | −62.0% | 0.1× | n/a |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.31M | n/a | 29.8× | n/a | 1.4× | n/a | 0.3× | n/a |
| Cloudbreak Pharma, Inc. · HKEX:2592 | US$140.4M | US$82.05M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Protara Therapeutics, Inc. · NASDAQ:TARA | US$140.4M | US$15.77M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.12 |
| Scancell Holdings PLC · LSE:SCLP | US$140.3M | US$155.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Abeona Therapeutics Inc. · NASDAQ:ABEO | US$138.4M | US$15.29M | n/a | 0.4× | n/a | 1.1× | −160.3% | 0.1× | 1.00 |
| DX & VX Co., Ltd. · KRX:180400 | US$133.8M | US$99.99M | n/a | 5.1× | n/a | 2.2× | −99.2% | 0.1× | n/a |
| Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL | US$133.6M | −US$62.81M | n/a | n/a | n/a | 0.7× | n/a | 0.2× | 1.44 |
| Sionna Therapeutics, Inc. · NASDAQ:SION | US$127.8M | −US$89.05M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.51 |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.2M | US$94.42M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| IntoCell, Inc. · KRX:287840 | US$126.6M | US$108.8M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| Median of the others | US$136.1M | US$86.68M | 17.5× | 1.4× | −160.3% | 0.0× | 1.28 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.22 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.030 · 1 analyst
- Revenue, year to Jun 2027
- 6.3M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Cheryl Maley | Chief Executive Officer & Managing Director |
| Justin Cahill | Chief Financial and Operations Officer & Company Secretary |
| Sindy Smith | Senior Communications & Investor Relations Manager |
| Amanda Reese | Vice President, Business Development |
| Brian Kelly | Director, Manufacture & Laboratory Operations |
| Graham Heery | Director, Translational Science & CMC |
| Jeremy Paull | Chief Scientific and Regulatory Officer |
| Miranda Sowden | Director, People & Culture |
| Richard Hufton | Director, Discovery Research |
Board
| Director | Role |
|---|---|
| David McIntyre | Independent Non-Executive Director - Chair, Audit & Risk Committee |
| Jeff Davies | Independent Non-Executive Director |
| Lynda Cheng | Independent Non-Executive Director - Chair, Remuneration & Nomination Committee |
| Russell Basser | Independent Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Nov 28, 2025 | −2.6% |
| Q4 2025 | Aug 20, 2025 · Before open | 0.0% |
| Quarter to Mar 31, 2025 | May 28, 2025 | 0.0% |
| Q2 2025 | Mar 4, 2025 | −4.3% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | +9.5% |
| Q4 2024 | Aug 26, 2024 | +4.4% |
| Quarter to Mar 31, 2024 | May 29, 2024 | −4.2% |
| Q2 2024 | Feb 27, 2024 | +4.0% |
| Quarter to Sep 30, 2023 | Oct 31, 2023 · Before open | 0.0% |
| Q4 2023 | Aug 24, 2023 · Before open | −3.5% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Apr 28, 2023 · Before open | 0.0% |
| Q2 2023 | Feb 28, 2023 · Before open | −2.6% |
| Q1 2023 | Nov 8, 2022 | +7.1% |
| Q4 2022 | Aug 24, 2022 · After close | −3.5% |
| Q3 2022 | Jun 1, 2022 | −2.1% |
| Q2 2022 | Feb 20, 2022 · After close | −5.3% |
| Q1 2022 | Nov 9, 2021 | +1.4% |
| Q4 2021 | Aug 24, 2021 | −1.6% |
| Q2 2021 | Feb 24, 2021 | −2.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (November 2026) | Shareholder meeting | 31 slides | Nov 6, 2026 |
| Investor Presentation (October 2026) | Investor deck | 17 slides | Oct 21, 2026 |
| Investor Presentation (July 2026) | Investor deck | 45 slides | Jul 15, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 35 slides | Nov 14, 2025 |
| Australian Microcap Investment Conference 2025 | Conference | 27 slides | Oct 21, 2025 |
| Merger or Acquisition (September 2025) | Merger or acquisition | 8 slides | Sep 22, 2025 |
| PepTalk 2025, Targeted Radioligand Therapies | Conference | 28 slides | Jan 16, 2025 |
| 6th Targeted Radiopharmaceuticals Summit Europe (December 2024) | Conference | 30 slides | Dec 4, 2024 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 43 slides | Nov 26, 2024 |
| Bell Potter Healthcare Conference 2024 | Conference | 19 slides | Nov 18, 2024 |
Show 50 decks
This page holds 50 of 67 decks. Open Decks
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.1M | 4.91M | 8.29M | 2.94M | 4.68M | 1.80M | 6.03M | 2.72M | 4.96M | 3.65M |
| Cost of revenue | 1.66M | 1.22M | 632.0K | 1.72M | 2.78M | 1.26M | 1.80M | 251.0K | 0 | 0 |
| Gross profit | 10.4M | 3.69M | 7.66M | 1.22M | 1.91M | 539.5K | 4.23M | 2.47M | 4.96M | 3.65M |
| Research and development | 22.3M | 8.36M | 15.6M | 18.9M | 18.9M | 22.3M | 20.5M | 15.5M | 14.6M | 18.1M |
| Selling, general and administrative | 3.20M | 3.03M | 3.57M | 3.77M | 3.29M | 4.02M | 2.67M | 2.50M | 2.24M | 2.94M |
| Operating income | -19.2M | -12.0M | -15.2M | -24.7M | -23.9M | -28.7M | -21.4M | -14.3M | -10.3M | -15.2M |
| Depreciation and amortization | 911.0K | 1.07M | 1.11M | 1.19M | 1.08M | 935.0K | 911.0K | 298.0K | 311.0K | 318.0K |
| EBITDA | -18.3M | -10.9M | -14.0M | -23.5M | -22.8M | -27.7M | -20.5M | -14.0M | -9.97M | -14.9M |
| Interest expense | 217.0K | 0 | 0 | 0 | 0 | 1.00K | ||||
| Income before tax | -18.6M | -9.99M | -13.7M | -23.3M | -23.4M | -27.0M | -20.3M | -14.3M | -10.3M | -15.2M |
| Income tax | -11.1M | -8.36M | -5.53M | -7.63M | -7.26M | -7.25M | -5.67M | -5.07M | -4.06M | -3.25M |
| Net income | -7.46M | -9.99M | -8.16M | -15.6M | -16.2M | -19.7M | -14.7M | -14.3M | -10.3M | -15.2M |
| Earnings per share, basic | -0.02 | -0.02 | -0.02 | -0.04 | -0.04 | -0.05 | -0.04 | -0.04 | -0.03 | -0.04 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.0M | 15.4M | 23.4M | 35.2M | 49.9M | 60.5M | 30.1M | 41.3M | 51.3M | 61.2M |
| Short-term investments | 0 | |||||||||
| Receivables | 4.39M | 4.22M | 6.34M | 8.23M | 7.84M | 8.44M | 6.09M | 959.0K | 5.91M | 3.84M |
| Inventory | 1.66M | 1.92M | 2.41M | 2.77M | 2.82M | 1.72M | 494.0K | 399.0K | 1 | |
| Current assets | 17.6M | 22.6M | 32.9M | 47.1M | 60.7M | 70.8M | 36.7M | 47.8M | 57.5M | 65.7M |
| Property, plant and equipment | 2.86M | 3.90M | 4.96M | 5.52M | 2.48M | 2.40M | 1.05M | 1.06M | 913.0K | |
| Goodwill | 0 | |||||||||
| Total assets | 19.0M | 25.4M | 36.8M | 52.1M | 66.2M | 73.2M | 39.1M | 48.9M | 58.5M | 66.6M |
| Accounts payable | 2.14M | 2.05M | 2.73M | 6.62M | 6.76M | 6.71M | 4.39M | 4.10M | 3.02M | 4.03M |
| Current liabilities | 5.17M | 5.23M | 6.66M | 14.5M | 10.2M | 10.4M | 6.70M | 6.43M | 5.16M | 5.52M |
| Long-term debt | 0 | 4.00M | 23.0K | 47.0K | ||||||
| Total debt | 707.0K | 2.40M | 3.53M | 8.27M | 8.19M | 1.17M | 1.57M | 26.0K | 49.0K | 70.0K |
| Total liabilities | 5.24M | 6.42M | 8.70M | 17.3M | 17.8M | 10.9M | 7.75M | 6.46M | 5.23M | 5.61M |
| Shareholders' equity | 13.8M | 19.0M | 28.1M | 34.8M | 48.4M | 62.3M | 31.3M | 42.4M | 53.3M | 61.0M |
| Shares outstanding | 430.8M | 417.2M | 411.4M | 409.0M | 406.9M | 396.9M | 372.2M | 371.3M | 370.1M | 368.2M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.21M | -6.76M | -6.98M | -13.5M | -13.2M | -14.8M | -10.8M | -10.3M | -10.2M | -17.0M |
| Capital spending | -287.0K | -42.0K | -89.0K | -621.0K | -837.0K | -246.0K | -125.0K | -314.0K | -359.0K | -625.0K |
| Free cash flow | -3.50M | -6.80M | -7.07M | -14.2M | -14.0M | -15.1M | -10.9M | -10.7M | -10.6M | -17.6M |
| Cash from investing | -259.0K | -42.0K | -89.0K | -610.0K | -836.0K | -246.0K | -125.0K | -306.0K | -359.0K | 32.7M |
| Cash from financing | -876.0K | -1.13M | -4.75M | -695.0K | 3.23M | 46.3M | -584.0K | -26.0K | -26.0K | -21.0K |
| Dividends paid | -46.3M | 0 | ||||||||
| Share buybacks | 0 | -1.93M | -1.93M | 0 | ||||||
| Change in cash | -4.39M | -7.95M | -11.8M | -14.7M | -10.6M | 30.4M | -11.2M | -10.1M | -9.87M | 15.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Chair and Deputy Chair Appointments | Nov 5, 2026 | Management or board change | ASX |
| Results of 2026 Annual General Meeting | Nov 5, 2026 | Meeting outcome | ASX |
| AGM Chair address and CEO presentation | Nov 5, 2026 | Meeting outcome | ASX |
| Becoming a substantial holder | Nov 2, 2026 | Ownership change notice | ASX |
| Application for quotation of securities - SPL | Oct 29, 2026 | Financing | ASX |
| Details of Company Address | Oct 23, 2026 | Other filings | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 21, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 21, 2026 | Quarterly report | ASX |
| $3.5 Million R&D Tax Incentive Received | Oct 21, 2026 | Other filings | ASX |
| Starpharma Investor Presentation Petalion Webinar | Oct 20, 2026 | Operations update | ASX |
Show 200 filings
This page holds 200 of 298 filings. Open Filings
Cap table
Built by 6ix from Starpharma Holdings Limited’s releases
- Common shares
- 479,739,115
- Fully diluted
- 479,739,115
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 479,739,115 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 479,739,115 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amanda Reese | Vice President, Business Development · Since at least Nov 7, 2026 |
| Brian Kelly | Director, Manufacture & Laboratory Operations · Since at least Nov 7, 2026 |
| Cheryl Maley | Chief Executive Officer & Managing Director · Since at least Sep 22, 2025 |
| David McIntyre | Independent Non-Executive Director - Chair, Audit & Risk Committee · Since at least Nov 7, 2026 |
| Graham Heery | Director, Translational Science & CMC · Since at least Nov 7, 2026 |
| Jeff Davies | Independent Non-Executive Director · Since at least Nov 7, 2026 |
| Jeremy Paull | Chief Scientific and Regulatory Officer · Since at least Nov 7, 2026 |
| Justin Cahill | Chief Financial and Operations Officer & Company Secretary · Since at least Oct 29, 2026 |
| Lynda Cheng | Independent Non-Executive Director - Chair, Remuneration & Nomination Committee · Since at least Nov 7, 2026 |
| Miranda Sowden | Director, People & Culture · Since at least Nov 7, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Richard Hufton | Director, Discovery Research · Since at least Nov 7, 2026 |
| Rob B Thomas | Independent Non-Executive Director - Chair, Board · Oct 1, 2026 – Nov 6, 2026 · Past |
| Rob Thomas | Chair · Until Nov 6, 2026 · Past |
| Russell Basser | Independent Non-Executive Director · Since at least Nov 7, 2026 |
| Sindy Smith | Senior Communications & Investor Relations Manager · Since at least Nov 7, 2026 |
Log in to ask 6ix AI your own questions about Starpharma Holdings Limited.